zantac 300 mg brusetabletter
paranova danmark a/s - ranitidinhydrochlorid - brusetabletter - 300 mg
zantac 25 mg/ml koncentrat til infusionsvæske, opløsning
glaxosmithkline pharma a/s - ranitidinhydrochlorid - koncentrat til infusionsvæske, opløsning - 25 mg/ml
zantac 150 mg brusetabletter
glaxosmithkline pharma a/s - ranitidinhydrochlorid - brusetabletter - 150 mg
zantac 300 mg brusetabletter
glaxosmithkline pharma a/s - ranitidinhydrochlorid - brusetabletter - 300 mg
zantac 150 mg filmovertrukne tabletter
glaxosmithkline pharma a/s - ranitidinhydrochlorid - filmovertrukne tabletter - 150 mg
enrylaze
jazz pharmaceuticals ireland limited - crisantaspase - forløbercellelimfoblastisk leukæmi-lymfom - antineoplastiske midler - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.
fastac 50 emulsionskoncentrat
basf a/s - alpha-cypermethrin - emulsionskoncentrat - 50 g/l alpha-cypermethrin
erwinase 10.000 e pulver til injektions-/infusionsvæske, opløsning
porton biopharma limited - crisantaspase - pulver til injektions-/infusionsvæske, opløsning - 10.000 e
fastac 99 emulsionskoncentrat
basf a/s - alpha-cypermethrin - emulsionskoncentrat - 100 g/l alpha-cypermethrin